Abstract
Introduction Haematological cancers are common in the UK, with a variety of morphologies. Stem cell transplants and chimeric antigen receptor (CAR) T-cell therapies provide significant options for hard to treat haematological cancers, although with difficult to predict outcomes. Research into the determinates of treatment efficacy, and access to treatments, is key to ensuring equal benefit across patients, and patient safety. With this, there are concerns about the small representation of minority groups in related research. We aim to report on the current knowledge, to guide future research.
Methods and analysis A variety of databases will be searched, for literature on UK minority ethnic populations receiving haematopoietic stem cell transplant or CAR T-cell therapy. Many outcomes will be analysed, covering the patient care pathway for those of the target population, although with a focus on follow-up after therapy. Plans have been made to conduct narrative synthesis, with meta-analysis where applicable.
Ethics and Dissemination Outputs will be published in an appropriate journal, and discussed with the wider NIHR Blood and Transplant Research Unit in Precision Transplant and Cellular Therapeutics (BTRU) group. Discussions will also be undertaken with the BTRU patient partners group.
Strengths and Limitations of this Study
This systematic review has a detailed search criteria with a variety of search tools, enabling high sensitivity in obtaining evidence.
To enable this work to be completed, reviewers will be working independently on separate reference lists, during screening, rather than voting on the same references and resolving conflicts. To alleviate issues, reviewers will be first required to screen a defined number of papers together, using a more classical approach to confirm agreement, before working independently.
Due to difficulties in pooling together international ethnic groups, only studies in the UK have been included, to reduce complexity. There are some ethnic groups which are more valid to pool together internationally than others, mainly in respect to genetic factors (as opposed to social), which this protocol does not consider.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute for Health and Care Research (NIHR) Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, University of Birmingham, UK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Joint senior authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors
